Background: Although the usefulness of plasma levels of B-type natriuretic peptide (BNP) as a prognostic indicator has been established for patients with heart failure (HF) with reduced ejection fraction (EF) (HFrEF, EF ≤ 40%), it remains unknown whether BNP is also a useful prognostic marker for HF with preserved EF (HFpEF, EF > 50%) or borderline HFpEF (40% < EF ≤ 50%). Methods and Results: We analyzed the data of 4301 consecutive chronic HF patients in stage C/D (mean 69 years, female 32%) in our CHART-2 Study (N = 10,219). During median 6.3-year follow up, 887, 218 and 330 all-cause deaths occurred in HFpEF (N = 2893), borderline HFpEF (N = 666) and HFrEF (N = 742), respectively. Although median BNP levels progressively increased from HFpEF, borderline HFpEF to HFrEF (85.3, 127 and 216 pg/mL, respectively P < .001), the relationship between log2 BNP levels and the mortality risk was comparable among the 3 groups. Moreover, log2 BNP levels were similarly associated with cardiovascular and non-cardiovascular deaths and HF admission in all groups. In addition, when evaluated with the cutoff BNP levels obtained by the survival CART (classification and regression trees) analysis, the mortality risk was effectively stratified by the BNP levels in each group; patients with 30–100, 100–300 and ≥300 pg/mL had comparably increasing mortality risk in all classes. Conclusion: BNP levels had comparable prognostic impacts among HFpEF, borderline HFpEF and HFrEF.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect